🧬 CMV Vaccine Tracker Dashboard
Tracking cytomegalovirus (CMV) vaccine development to prevent congenital CMV infection, the leading infectious cause of birth defects worldwide. CMV affects 1 in 200 babies (0.5-0.7% of all births), causing permanent disabilities including hearing loss, vision impairment, intellectual disability, and cerebral palsy. Two vaccines are currently in Phase 3 trials: Moderna's mRNA-1647 and GSK's glycoprotein B (gB/MF59) vaccine. This tracker monitors the complete CMV vaccine pipeline targeting maternal immunization, transplant recipients, and congenital infection prevention.
CMV Vaccines by Development Phase
2
Phase 3 Trials (Leading!)
1 in 200
Babies Born with CMV
🔬 Phase 3 Clinical Trials - LEADING CANDIDATES!
Technology
mRNA-LNP (6 antigens)
Target Population
Women 16-40 years
Phase 2 Results
50% efficacy vs primary infection
Phase 3 Size
~7,300 participants
Details: mRNA-1647 is Moderna's most complex mRNA vaccine, encoding six CMV antigens: glycoprotein B (gB), pentameric complex (PC - gH/gL/UL128/UL130/UL131A), and pp65. Phase 2 CMVictory trial in 6,500 women aged 16-40 demonstrated 50% efficacy preventing primary CMV infection over 42 months (NEJM 2024). Phase 3 CMVision trial launched 2024 with ~7,300 seronegative women globally. Three-dose regimen (0, 2, 6 months). If successful, could be first licensed CMV vaccine, available 2026-2027. Targets maternal immunization to prevent congenital CMV. Could prevent ~30,000 US cases annually of congenital CMV-related hearing loss and developmental delays.
Technology
Recombinant gB + MF59
Target Population
Postpartum women, transplant recipients
Phase 2 Efficacy
43-50% vs primary infection
Development Time
20+ years (longest-studied)
Description: GSK's gB/MF59 consists of recombinant CMV glycoprotein B with MF59 adjuvant (squalene-based emulsion). Longest-studied CMV vaccine with 20+ years development. Multiple Phase 2 trials showed 43-50% efficacy preventing primary infection and reducing viral load in transplant recipients. Three-dose regimen. Phase 3 trials ongoing in postpartum women and transplant recipients. Well-tolerated safety profile. Represents proven protein subunit approach used in licensed vaccines.
🧬 Phase 2 & Earlier Development
Phase 2 Candidates (3): Replication-defective CMV vaccines, DNA vaccines, VLP platforms. Phase 1 (4): Next-generation mRNA vaccines, viral vectors, novel adjuvant combinations. Preclinical (5): Self-amplifying RNA, nanoparticle vaccines, T cell-focused vaccines, therapeutic vaccines for transplant patients, broad herpesvirus vaccines.